Our balanced-risk approach to building a pipeline allows us to create a company with near-term value streams to fuel innovation

Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of close-to-market opportunities that have the potential to provide near-term value with cutting-edge programs that we believe have the potential to transform how we treat many infectious diseases, addressing significant unmet medical needs in patient care.

 

This approach allows Appili to seek productive collaborations with industry partners and federal government agencies whose objectives align with ours, while pursuing non-dilutive funding sources specifically earmarked for anti-infective development programs.

ATI-2307: A broad spectrum, clinical stage anti-fungal for serious fungal infections.
ATI-1701: Tackling a serious bioterrorism threat
ATI-1503: A new class of antibiotics to combat the most deadly Gram-negative bacteria
ATI-1501: A novel formulation of metronidazole for the growing number of patients who cannot comply with the current standard-of-care